C12Y 105/01003
Dihydrofolate reductase
Official title: Dihydrofolate reductase (1.5.1.3)
C12Y105/01003 (Dihydrofolate reductase) appears on 53 US grants and 104 published applications in this corpus.
Search patents in C12Y- Granted patents
- 53
- Published applications
- 104
- Assignees
- 58
- Inventors
- 235
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 2 |
| 2011 | 1 | 2 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 1 | 2 |
| 2015 | 2 | 4 |
| 2016 | 1 | 3 |
| 2017 | 4 | 5 |
| 2018 | 4 | 5 |
| 2019 | 1 | 9 |
| 2020 | 4 | 10 |
| 2021 | 4 | 12 |
| 2022 | 4 | 9 |
| 2023 | 3 | 8 |
| 2024 | 5 | 6 |
| 2025 | 9 | 9 |
| 2026 | 5 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Small molecules for dual function positron emission tomography (PET) and cell suicide switches4 Aug 2026US 12,697,403 B2The Trustees of the University of Pennsylvania
- IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy21 Apr 2026US 12,606,603 B2Seattle Children's Hospital
- Complement component 1s (C1s) deficient cells for production of vaccines and biopharmaceutical proteins24 Feb 2026US 12,559,526 B2The Regents of the University of California
- Destabilising domains for conditionally stabilising a protein27 Jan 2026US 12,534,711 B2Braingene AB
- Double knock-out CHO cell line method of its generation and producing therapeutic proteins therefrom20 Jan 2026US 12,529,048 B2Enzene Biosciences Limited
- Analytical device for real time luminescence during temperature hold and ramp as used in real time cellular thermal shift assay1 Oct 2026US 2026/0297593 A1The United States of America, as represented by the Secretary, Department of Health and Human Serv
- Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function24 Sep 2026US 2026/0284108 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Production cell lines with targeted integration sites17 Sep 2026US 2026/0275373 A1Seagen Inc.
- Peptide expression constructs and uses thereof20 Aug 2026US 2026/0242414 A1Kyoto Prefectural Public University Corporation
- Compositions and methods for tunable regulation of rnai23 Jul 2026US 2026/0209773 A1Obsidian Therapeutics, Inc.
Most cited
By later US patents
- Methods of generating desired amino-terminal residues in proteins51US 5,093,242 AMassachusetts Institute of Technology · 1992
- Combination therapy with an anti-hyaluronan agent and therapeutic agent23US 9,913,822 B2Halozyme, Inc. · 2018
- Protein enriched microvesicles and methods of making and using the same19US 9,593,356 B2Takara Bio USA, Inc. · 2017
- Polypeptides from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof13US 5,849,564 AThe Trustees of Columbia University in the City of New York · 1998
- Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias9US 11,060,098 B2Dna Twopointo Inc. · 2021